Healthcare Global Enterprises Share Price

Conference Call with Healthcare Global Enterprises Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 week 4 days ago

Revenue for the quarter at 650.29 crore

• Business Line
• 1 week 4 days ago

Healthcare Facilities company Healthcare Global Enterprises announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from Operations: Consolidated revenue from operations for Q4FY26 was Rs 65,029 lakh, a QoQ increase of 3.03% from Rs 63,118 lakh and a YoY growth of 11.46% from Rs 58,343 lakh. Total Income: Total consolidated income for Q4FY26 stood at Rs 66,540 lakh, up 4.70% QoQ from Rs 63,554 lakh and up 11.76% YoY from Rs 59,539 lakh. Profit for the Period: The company reported a consolidated profit of Rs 404 lakh in Q4FY26, recovering from a loss of Rs 790 lakh in Q3FY26. However, this was a 40.33% decrease YoY from Rs 677 lakh in Q4FY25. Annual Revenue (FY26): Consolidated revenue for FY26 reached Rs 2,53,843 lakh, an increase of 14.44% over Rs 2,21,814 lakh in FY25. Annual Profit (FY26): Consolidated profit for the year FY26 was Rs 2,278 lakh, a decrease of 53.35% compared to Rs 4,883 lakh in FY25. Total Comprehensive Income: Consolidated total comprehensive income for Q4FY26 was Rs 569 lakh, compared to a loss of Rs 582 lakh in Q3FY26 and a profit of Rs 698 lakh in Q4FY25. Standalone Financial Highlights: Revenue from Operations: The company reported revenue from operations of Rs 34,847 lakh in Q4FY26, showing a QoQ growth of 2.32% compared to Rs 34,056 lakh in Q3FY26, and a YoY increase of 7.95% compared to Rs 32,280 lakh in Q4FY25. Total Income: Total income for Q4FY26 stood at Rs 36,513 lakh, up 5.79% QoQ from Rs 34,515 lakh and up 9.37% YoY from Rs 33,384 lakh. Profit for the Period: The company recorded a profit of Rs 153 lakh in Q4FY26, compared to a loss of Rs 118 lakh in Q3FY26. On a YoY basis, profit decreased by 84.93% from Rs 1,015 lakh in Q4FY25. Annual Revenue (FY26): For the full year FY26, revenue from operations reached Rs 1,35,937 lakh, representing a growth of 6.49% over Rs 1,27,652 lakh in FY25. Annual Total Income (FY26): Total income for FY26 was Rs 1,39,497 lakh, up 6.07% from Rs 1,31,510 lakh in FY25. Annual Profit (FY26): Profit for the year FY26 significantly increased to Rs 1,458 lakh, a growth of 313.03% compared to Rs 353 lakh in FY25. Total Comprehensive Income: For Q4FY26, total comprehensive income was Rs 142 lakh, compared to a loss of Rs 88 lakh in Q3FY26 and a profit of Rs 1,046 lakh in Q4FY25. Business Highlights: Divestment of BACC: The Board approved the divestment of the company's entire equity shareholding in BACC Health Care Private Limited (BACC) to Inviga Healthcare Fund I for a consideration of Rs 3,764 lakh. BACC is engaged in fertility and reproductive healthcare, which is not considered a core business for the company. Rights Issue Completion: During Q4FY26, the company completed a rights issue of 8,294,566 equity shares at an issue price of Rs 512 per share, resulting in an increase of paid-up equity share capital by Rs 829 lakh and a securities premium reserve of Rs 41,639 lakh. Strategic Acquisitions: Subsequent to March 31, 2026, the company completed the acquisition of an additional 34% equity share capital of Vizag Hospital and Cancer Research Centre Private Limited (VHCRPL) on April 13, 2026, for Rs 15,450 lakh. Exceptional Items: The company recognized an impairment loss of Rs 3,752 lakh (standalone) and Rs 3,191 lakh (consolidated) related to the planned divestment of BACC. An impairment of Rs 3,000 lakh was recorded for HCG Kolkata Cancer Care LLP, while an impairment reversal of Rs 2,000 lakh was recognized for HCG Manavata Oncology LLP due to improved performance. Incremental impacts from the notification of new Labour Codes resulted in exceptional costs of Rs 786 lakh (standalone) and Rs 1,267 lakh (consolidated) during the previous quarter. Segment Performance: The company has reported that it operates in a single operating segment, which is "setting up and managing hospitals and medical diagnostic services." Leadership Appointments: Mr. Sanjeev Kumar was appointed as the Chief Financial Officer and Key Managerial Personnel effective May 25, 2026. Mr. Ravi Gothwal was appointed as AVP - Investor Relations and designated as Senior Management Personnel effective May 19, 2026. Tax Reversals: Income tax expenses for the year ended March 31, 2026, are net of Rs 1,820 lakh relating to the reversal of income taxes from earlier years. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises, said, “Cancer care is no longer only about treatment - it is about early diagnosis, precision, continuity of care, and improving quality of life for patients and families. Over the years, HCG has built a strong oncology ecosystem anchored in clinical excellence, multidisciplinary expertise, technology, and compassionate patient care. What differentiates us is our ability to bring together specialists, advanced diagnostics, research, and personalized treatment pathways under one integrated platform. As we look ahead, our focus is on strengthening next-generation oncology capabilities across precision medicine, molecular diagnostics, genomics, robotics, and data-driven clinical decision-making. These advancements will play a critical role in detecting cancer earlier, reducing recurrence, improving outcomes, and making personalized cancer care more accessible to patients across India. India has a significant opportunity to redefine the future of cancer care, and HCG remains committed to contributing meaningfully to this transformation through innovation, research, academic collaborations, and expansion of centres of excellence delivering globally benchmarked outcomes. Our purpose continues to remain clear - to make high-quality cancer care affordable, accessible, and patient-centric, while positively impacting millions of lives.” Manish Mattoo, CEO, HealthCare Global Enterprises, said, “We concluded FY26 on a strong note, with our Q4 and full-year performance reflecting consistent execution across our network and reinforcing our conviction in the strength and distinctiveness of HCG’s cancer-focused platform. For the full year, revenues grew by 15% to Rs 25,454 million, with performance remaining well-balanced across regional clusters, supported by resilient demand for high-quality oncology care across medical, radiation, and surgical modalities. Adjusted EBITDA for FY26 grew by 19% to Rs 4,711 million, with margins at 18.5%, reflecting operating leverage driven by improving throughput, better capacity utilisation, and disciplined cost management. This strong performance was sustained in Q4FY26, with adjusted EBITDA increasing by 17% to Rs 1,252 million and margins expanding to 19.2%, underscoring continued momentum in operating performance. Overall, our performance demonstrates the scalability of our model and the depth of our clinical capabilities, backed by a sustained focus on outcomes and patient-centric care. A key milestone during the year was the successful completion of our Rs 4,250 million rights issue, which further strengthened our financial foundation and gives us greater flexibility to invest behind our long-term priorities - including capacity expansion, clinical infrastructure upgrades, technology investments and selective growth opportunities - while continuing to maintain a disciplined, returns-focused approach. HCG’s integrated care model continues to be a key differentiator, anchored in tumour-board-led clinical decision-making, consistent clinical outcomes, and the trust built over more than two decades. We remain focused on driving higher asset utilisation, deepening clinical excellence, and expanding our network selectively, while staying anchored to our core purpose of delivering high-quality, accessible cancer care.” Result PDF

• Trendlyne
• 1 week 4 days ago